Independent Medical Education Request for Proposals - Diffuse Large B-cell Lymphoma
Funds independent medical education projects to advance evidence-based care and knowledge in Diffuse Large B-Cell Lymphoma, focusing on clinical gaps and novel therapies for community healthcare professionals.
Funder: Roche
Due Dates: May 15, 2026: Full application submission deadline for the 2026 Independent Medical Education RFP (Diffuse Large B‑Cell Lymphoma)
Funding Amounts: Up to $150,000 per award; typically for single-year, U.S.-based educational initiatives.
Summary: Supports independent medical education projects to advance knowledge and care in Diffuse Large B-Cell Lymphoma.
Key Information: Only U.S.-based, accredited CME/CE providers are eligible; “2026 DLBCL RFP” must be included in the program title.
Description
This opportunity, funded by Genentech (a member of the Roche Group), seeks proposals for independent, certified medical education projects focused on Diffuse Large B-Cell Lymphoma (DLBCL). The aim is to support high-quality, evidence-based educational initiatives that address clinical and logistical gaps in the diagnosis, treatment, and management of DLBCL—especially for relapsed/refractory patients who are not candidates for, or lack access to, advanced cellular therapies. Projects should enhance the knowledge and competence of community-based healthcare professionals, helping them incorporate novel therapies and optimize care coordination for DLBCL patients.
